Home
VERV
VERV News

Latest Verve Therapeutics Inc. (VERV) News on July 8, 2025

Investing.com

11 days ago

BMO downgrades Verve Therapeutics saying Lilly buyout deal caps upside

MT Newswires

11 days ago

BMO Capital Downgrades Verve Therapeutics to Market Perform, $13.50 Price Target

Lilly To Acquire Verve For One-Time Cardiovascular Treatments

Insider Monkey

15 days ago

Lilly To Acquire Verve For One-Time Cardiovascular Treatments

Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week

Motley Fool

18 days ago

Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week

What is the Intent Behind Eli Lilly's Recent M&A Deals Spree?

Zacks

19 days ago

What is the Intent Behind Eli Lilly's Recent M&A Deals Spree?

SanDisk initiated, Analog Devices upgraded: Wall Street’s top analyst calls

TipRanks

19 days ago

SanDisk initiated, Analog Devices upgraded: Wall Street’s top analyst calls

Verve Therapeutics downgraded to Hold from Buy at Canaccord

TipRanks

20 days ago

Verve Therapeutics downgraded to Hold from Buy at Canaccord

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement

Zacks

20 days ago

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement

MT Newswires

20 days ago

Canaccord Genuity Downgrades Verve Therapeutics to Hold From Buy

MT Newswires

20 days ago

William Blair Downgrades Verve Therapeutics to Market Perform From Outperform

MT Newswires

20 days ago

Jefferies Downgrades Verve Therapeutics to Hold From Buy, Adjusts Price Target to $11 From $28

MT Newswires

20 days ago

HC Wainwright Downgrades Verve Therapeutics to Neutral From Buy, $25 Price Target

Podcast: U.S. Stocks Slip as Israel-Iran Conflict Continues

The Wall Street Journal

20 days ago

Podcast: U.S. Stocks Slip as Israel-Iran Conflict Continues

Stocks to Watch Recap: T-Mobile, Eli Lilly, Verve Therapeutics, First Solar

The Wall Street Journal

21 days ago

Stocks to Watch Recap: T-Mobile, Eli Lilly, Verve Therapeutics, First Solar

These Stocks Moved the Most Today: Sunrun, Enphase, Verve Therapeutics, Palantir, Tesla, T-Mobile, Jabil, and More

Barrons.com

21 days ago

These Stocks Moved the Most Today: Sunrun, Enphase, Verve Therapeutics, Palantir, Tesla, T-Mobile, Jabil, and More

Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover

Investor's Business Daily

21 days ago

Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover

T-Mobile & Softbank, solar, Eli Lilly & Verve: Trending Tickers

Yahoo Finance Video

21 days ago

T-Mobile & Softbank, solar, Eli Lilly & Verve: Trending Tickers

These Stocks Are Moving the Most Today: Sunrun, Enphase, Verve Therapeutics, Palantir, T-Mobile, Lennar, Jabil, and More

Barrons.com

21 days ago

These Stocks Are Moving the Most Today: Sunrun, Enphase, Verve Therapeutics, Palantir, T-Mobile, Lennar, Jabil, and More

Eli Lilly Strikes up to $1.3 Billion Deal to Buy Verve Therapeutics

MT Newswires

21 days ago

Eli Lilly Strikes up to $1.3 Billion Deal to Buy Verve Therapeutics

MT Newswires

21 days ago

Fed Policy-Setting Meeting Begins as US Equity Futures Decline Pre-Bell

MT Newswires

21 days ago

Sector Update: Health Care

Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B

Investopedia

21 days ago

Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B

MT Newswires

21 days ago

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Amid Escalating Iran-Israel Conflict

What Makes Verve Therapeutics (VERV) a New Buy Stock

Zacks

25 days ago

What Makes Verve Therapeutics (VERV) a New Buy Stock

Verve Therapeutics (VERV) Just Reclaimed the 200-Day Moving Average

Zacks

a month ago

Verve Therapeutics (VERV) Just Reclaimed the 200-Day Moving Average

Wall Street Analysts See a 367.86% Upside in Verve Therapeutics (VERV): Can the Stock Really Move This High?

Zacks

a month ago

Wall Street Analysts See a 367.86% Upside in Verve Therapeutics (VERV): Can the Stock Really Move This High?

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a month ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Verve Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire

a month ago

Verve Therapeutics to Participate in Upcoming Investor Conferences

3 Top Genomics Stocks to Add to Your Portfolio in 2025

Zacks

2 months ago

3 Top Genomics Stocks to Add to Your Portfolio in 2025

Verve Therapeutics Leads The Charge With 2 Other Promising Penny Stocks

Simply Wall St.

2 months ago

Verve Therapeutics Leads The Charge With 2 Other Promising Penny Stocks

Analyst Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher

Simply Wall St.

2 months ago

Analyst Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher

Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates

Zacks

2 months ago

Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates

Associated Press Finance

2 months ago

Verve Therapeutics: Q1 Earnings Snapshot

Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results

GlobeNewswire

2 months ago

Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 months ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall Street

Motley Fool

2 months ago

1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall Street

Why Verve Therapeutics Zoomed 40% Higher This Week

Motley Fool

3 months ago

Why Verve Therapeutics Zoomed 40% Higher This Week

Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News

Zacks

3 months ago

Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News

MT Newswires

3 months ago

Verve Therapeutics Shares Jump After Cantor Fitzgerald Upgrade

Why Verve Therapeutics Is Skyrocketing Today

Motley Fool

3 months ago

Why Verve Therapeutics Is Skyrocketing Today

VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study

Zacks

3 months ago

VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study

MT Newswires

3 months ago

Cantor Fitzgerald Upgrades Verve Therapeutics to Overweight From Neutral

Clover Health Investments Leads The Charge In These 3 Promising Penny Stocks

Simply Wall St.

3 months ago

Clover Health Investments Leads The Charge In These 3 Promising Penny Stocks

Verve’s shares jump by more than 26% on Lilly-partnered gene therapy data

Pharmaceutical Technology

3 months ago

Verve’s shares jump by more than 26% on Lilly-partnered gene therapy data

This Cholesterol Gene Medicine Could Work in 1 Shot. It Could Also Bring This Biotech Stock Back to Life.

Barrons.com

3 months ago

This Cholesterol Gene Medicine Could Work in 1 Shot. It Could Also Bring This Biotech Stock Back to Life.

MT Newswires

3 months ago

Sector Update: Health Care Stocks Rise Pre-Bell Monday

MT Newswires

3 months ago

Top Premarket Gainers

MT Newswires

3 months ago

Verve Therapeutics' VERVE-102 Gene Editing Therapy Trial Shows Positive Initial Data in Clinical Trial

Verve’s second swing at gene editing for heart disease shows early promise

BioPharma Dive

3 months ago

Verve’s second swing at gene editing for heart disease shows early promise

Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

GlobeNewswire

3 months ago

Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

MT Newswires

3 months ago

Sector Update: Health Care Stocks Mixed Premarket Friday

MT Newswires

3 months ago

Verve Therapeutics Gets FDA Fast Track Designation for VERVE-102

Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

GlobeNewswire

3 months ago

Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

3 months ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks

3 months ago

Biotech stocks slide as Marks resignation seen being negative for sector

Is Verve Therapeutics, Inc. (VERV) the Best Gene-Editing Stock to Buy?

Insider Monkey

3 months ago

Is Verve Therapeutics, Inc. (VERV) the Best Gene-Editing Stock to Buy?

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

GlobeNewswire

3 months ago

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

Verve gets FDA green light to expand base editing trial into US

BioPharma Dive

3 months ago

Verve gets FDA green light to expand base editing trial into US

MT Newswires

3 months ago

Verve Therapeutics Says US FDA Clears Verve-102 IND Application for Premature Coronary Artery Disease

Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose

GlobeNewswire

3 months ago

Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose

MT Newswires

4 months ago

RBC Cuts Price Target on Verve Therapeutics to $15 From $17, Keeps Outperform, Speculative Risk

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

4 months ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Verve Therapeutics Full Year 2024 Earnings: Beats Expectations

Simply Wall St.

4 months ago

Verve Therapeutics Full Year 2024 Earnings: Beats Expectations

Verve Therapeutics (VERV) Reports Q4 Loss, Tops Revenue Estimates

Zacks

4 months ago

Verve Therapeutics (VERV) Reports Q4 Loss, Tops Revenue Estimates

Associated Press Finance

4 months ago

Verve Therapeutics: Q4 Earnings Snapshot

Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire

4 months ago

Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

Vertex ends gene editing research pact with Verve

BioPharma Dive

4 months ago

Vertex ends gene editing research pact with Verve

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

5 months ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference

GlobeNewswire

5 months ago

Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Simply Wall St.

5 months ago

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Verve Therapeutics (VERV) Moves 18.7% Higher: Will This Strength Last?

Zacks

5 months ago

Verve Therapeutics (VERV) Moves 18.7% Higher: Will This Strength Last?

Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones

GlobeNewswire

6 months ago

Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones

Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

6 months ago

Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

6 months ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Why Is Verve Therapeutics, Inc. (VERV) Among the Top CRISPR Stocks to Invest In?

Insider Monkey

6 months ago

Why Is Verve Therapeutics, Inc. (VERV) Among the Top CRISPR Stocks to Invest In?

Verve Therapeutics, Inc. (VERV): Is This Gene Therapy Stock a Good Buy Right Now?

Insider Monkey

6 months ago

Verve Therapeutics, Inc. (VERV): Is This Gene Therapy Stock a Good Buy Right Now?

Verve Therapeutics Slides As Insider Purchases Lose Another US$65k

Simply Wall St.

7 months ago

Verve Therapeutics Slides As Insider Purchases Lose Another US$65k

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

7 months ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

8 months ago

RBC Capital Adjusts Price Target on Verve Therapeutics to $17 From $20, Maintains Outperform, Speculative Risk Rating

Verve Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

8 months ago

Verve Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Verve Therapeutics (VERV) Reports Q3 Loss, Tops Revenue Estimates

Zacks

8 months ago

Verve Therapeutics (VERV) Reports Q3 Loss, Tops Revenue Estimates

Associated Press Finance

8 months ago

Verve Therapeutics: Q3 Earnings Snapshot

Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results

GlobeNewswire

8 months ago

Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

8 months ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

State Street Corp's Strategic Acquisition in Verve Therapeutics

GuruFocus.com

9 months ago

State Street Corp's Strategic Acquisition in Verve Therapeutics

Is Verve Therapeutics, Inc. (VERV) the Best NASDAQ Stock Under $5?

Insider Monkey

9 months ago

Is Verve Therapeutics, Inc. (VERV) the Best NASDAQ Stock Under $5?

Jim Cramer on Vertiv Holdings (VRT): ‘I Think It’s A Winner’

Insider Monkey

10 months ago

Jim Cramer on Vertiv Holdings (VRT): ‘I Think It’s A Winner’

Millennium Management LLC's Strategic Acquisition in Verve Therapeutics Inc

GuruFocus.com

10 months ago

Millennium Management LLC's Strategic Acquisition in Verve Therapeutics Inc

Verve Therapeutics, Inc. (VERV): Among the Worst ARK Stocks According to Short Sellers

Insider Monkey

10 months ago

Verve Therapeutics, Inc. (VERV): Among the Worst ARK Stocks According to Short Sellers

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

10 months ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

a year ago

RBC Capital Adjusts Price Target on Verve Therapeutics to $20 From $25, Maintains Outperform Rating

Verve Therapeutics (VERV) Reports Q2 Loss, Lags Revenue Estimates

Zacks

a year ago

Verve Therapeutics (VERV) Reports Q2 Loss, Lags Revenue Estimates

Associated Press Finance

a year ago

Verve Therapeutics: Q2 Earnings Snapshot

Verve Therapeutics Announces Pipeline Progress and Reports Second Quarter 2024 Financial Results

GlobeNewswire

a year ago

Verve Therapeutics Announces Pipeline Progress and Reports Second Quarter 2024 Financial Results

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate

Simply Wall St.

a year ago

We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate

MT Newswires

a year ago

RBC Cuts Price Target on Verve Therapeutics to $25 From $35, Keeps Outperform, Speculative Risk

Why Is Verve Therapeutics, Inc. (VERV) the Most Shorted Stock Loved by Analysts Now?

Insider Monkey

a year ago

Why Is Verve Therapeutics, Inc. (VERV) the Most Shorted Stock Loved by Analysts Now?

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors

GlobeNewswire

a year ago

Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors

Share on Social Networks: